3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
NET
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Fluorodeoxyglucose F18
2
tivozanib
1
tislelizumab
1
surufatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
alectinib
1
Quality of Life
1
Patient Reported Outcome Measures
1
PM 01183
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lactones
1
Irinotecan
1
Interleukin-2
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
regorafenib
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled